Bioptigen Wins $458K Loan for Validation of Intrasurgical OCT System
Bioptigen has been awarded a $458,000 strategic growth loan from the North Carolina Biotechnology Center to support clinical validation of the company’s intrasurgical optical coherence tomography (OCT) imaging system.
The EnFocus system will provide 3-D visualization simultaneous with, and co-registered to, images from surgical ophthalmic microscopes. The device is intended to enable precision surgery with better patient outcomes and reduce the need for postsurgical follow-up procedures.
In September, Bioptigen received grants totaling $1.72 million from the National Eye Institute for development of the technology.
The company’s OCT imaging devices are sold to pediatric and surgical ophthalmology clinics and hospitals, and academic ophthalmology research centers globally.
For more information, visit
www.bioptigen.com.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024